The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review.

ABSTRACT:

Background

Substance use disorders (SUDs) remain a major global health challenge with limited pharmacological treatment options and high relapse rates. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes and obesity, have recently gained attention for their potential effects on addictive behaviors. Preclinical and early clinical studies suggest that GLP-1RAs modulate mesolimbic dopaminergic signaling and attenuate reward-driven behaviors, positioning them as promising candidates for novel interventions in addiction medicine.

Methods

We conducted a systematic literature review in accordance with PRISMA 2020 guidelines, with protocol registration in PROSPERO (CRD42024571356). Searches were performed across PubMed, Embase, Web of Scien

SUBMITTER: Volker KM 

PROVIDER: S-EPMC12808432 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature